JP2003523336A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003523336A5 JP2003523336A5 JP2001560192A JP2001560192A JP2003523336A5 JP 2003523336 A5 JP2003523336 A5 JP 2003523336A5 JP 2001560192 A JP2001560192 A JP 2001560192A JP 2001560192 A JP2001560192 A JP 2001560192A JP 2003523336 A5 JP2003523336 A5 JP 2003523336A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkynyl
- alkenyl
- group
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 description 48
- 125000003342 alkenyl group Chemical group 0.000 description 27
- 125000000304 alkynyl group Chemical group 0.000 description 27
- 239000008194 pharmaceutical composition Substances 0.000 description 22
- 150000001875 compounds Chemical class 0.000 description 21
- 125000003118 aryl group Chemical group 0.000 description 15
- 229910052799 carbon Inorganic materials 0.000 description 15
- 125000001153 fluoro group Chemical group F* 0.000 description 15
- 125000000623 heterocyclic group Chemical group 0.000 description 15
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 12
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 229910052739 hydrogen Inorganic materials 0.000 description 11
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 10
- 239000003112 inhibitor Substances 0.000 description 10
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 9
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 9
- 125000000753 cycloalkyl group Chemical group 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 7
- 125000005843 halogen group Chemical group 0.000 description 7
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 7
- 201000001320 Atherosclerosis Diseases 0.000 description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 6
- 208000031226 Hyperlipidaemia Diseases 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- 229910052801 chlorine Inorganic materials 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 125000001072 heteroaryl group Chemical group 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 229910052717 sulfur Inorganic materials 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 4
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 4
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 4
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 4
- 208000032928 Dyslipidaemia Diseases 0.000 description 4
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 4
- 208000035150 Hypercholesterolemia Diseases 0.000 description 4
- 208000017170 Lipid metabolism disease Diseases 0.000 description 4
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- 102000002072 Non-Receptor Type 1 Protein Tyrosine Phosphatase Human genes 0.000 description 4
- 108010015847 Non-Receptor Type 1 Protein Tyrosine Phosphatase Proteins 0.000 description 4
- 102000023984 PPAR alpha Human genes 0.000 description 4
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 4
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 4
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 4
- 210000001789 adipocyte Anatomy 0.000 description 4
- 229960005370 atorvastatin Drugs 0.000 description 4
- GPUADMRJQVPIAS-QCVDVZFFSA-M cerivastatin sodium Chemical compound [Na+].COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 GPUADMRJQVPIAS-QCVDVZFFSA-M 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 229960003765 fluvastatin Drugs 0.000 description 4
- 208000006575 hypertriglyceridemia Diseases 0.000 description 4
- 230000004968 inflammatory condition Effects 0.000 description 4
- 229960004844 lovastatin Drugs 0.000 description 4
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 4
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 4
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 4
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 4
- 229960002797 pitavastatin Drugs 0.000 description 4
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 4
- 229960002965 pravastatin Drugs 0.000 description 4
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 4
- LALFOYNTGMUKGG-BGRFNVSISA-L rosuvastatin calcium Chemical compound [Ca+2].CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O.CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O LALFOYNTGMUKGG-BGRFNVSISA-L 0.000 description 4
- 229960002855 simvastatin Drugs 0.000 description 4
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 3
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 2
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 2
- MVQVNTPHUGQQHK-UHFFFAOYSA-N 3-pyridinemethanol Chemical compound OCC1=CC=CN=C1 MVQVNTPHUGQQHK-UHFFFAOYSA-N 0.000 description 2
- NFFXEUUOMTXWCX-UHFFFAOYSA-N 5-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]-2-methoxy-n-[[4-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound C1=C(C(=O)NCC=2C=CC(=CC=2)C(F)(F)F)C(OC)=CC=C1CC1SC(=O)NC1=O NFFXEUUOMTXWCX-UHFFFAOYSA-N 0.000 description 2
- NKOHRVBBQISBSB-UHFFFAOYSA-N 5-[(4-hydroxyphenyl)methyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(O)=CC=C1CC1C(=O)NC(=O)S1 NKOHRVBBQISBSB-UHFFFAOYSA-N 0.000 description 2
- MVDXXGIBARMXSA-PYUWXLGESA-N 5-[[(2r)-2-benzyl-3,4-dihydro-2h-chromen-6-yl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1CC1=CC=C(O[C@@H](CC=2C=CC=CC=2)CC2)C2=C1 MVDXXGIBARMXSA-PYUWXLGESA-N 0.000 description 2
- 208000004611 Abdominal Obesity Diseases 0.000 description 2
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 229940123208 Biguanide Drugs 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 206010065941 Central obesity Diseases 0.000 description 2
- 229920001268 Cholestyramine Polymers 0.000 description 2
- 229920002911 Colestipol Polymers 0.000 description 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 2
- 208000002705 Glucose Intolerance Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 229940122355 Insulin sensitizer Drugs 0.000 description 2
- 108090000189 Neuropeptides Proteins 0.000 description 2
- 102000003797 Neuropeptides Human genes 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- 229940122054 Peroxisome proliferator-activated receptor delta agonist Drugs 0.000 description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 229940124639 Selective inhibitor Drugs 0.000 description 2
- 229940100389 Sulfonylurea Drugs 0.000 description 2
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 229960002632 acarbose Drugs 0.000 description 2
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 239000000048 adrenergic agonist Substances 0.000 description 2
- 229940126157 adrenergic receptor agonist Drugs 0.000 description 2
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 239000000883 anti-obesity agent Substances 0.000 description 2
- 229940125710 antiobesity agent Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 229940064856 azulfidine Drugs 0.000 description 2
- 229940076810 beta sitosterol Drugs 0.000 description 2
- 102000016959 beta-3 Adrenergic Receptors Human genes 0.000 description 2
- 108010014502 beta-3 Adrenergic Receptors Proteins 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 2
- 150000004283 biguanides Chemical class 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000001906 cholesterol absorption Effects 0.000 description 2
- 229960001214 clofibrate Drugs 0.000 description 2
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 2
- GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 description 2
- 229960002604 colestipol Drugs 0.000 description 2
- 229960004597 dexfenfluramine Drugs 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 229950002375 englitazone Drugs 0.000 description 2
- 229960001582 fenfluramine Drugs 0.000 description 2
- 229960002297 fenofibrate Drugs 0.000 description 2
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 2
- MQOBSOSZFYZQOK-UHFFFAOYSA-N fenofibric acid Chemical class C1=CC(OC(C)(C)C(O)=O)=CC=C1C(=O)C1=CC=C(Cl)C=C1 MQOBSOSZFYZQOK-UHFFFAOYSA-N 0.000 description 2
- 229960003627 gemfibrozil Drugs 0.000 description 2
- 229960001381 glipizide Drugs 0.000 description 2
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 201000010066 hyperandrogenism Diseases 0.000 description 2
- 229940121380 ileal bile acid transporter inhibitor Drugs 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 206010024627 liposarcoma Diseases 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- 229960003105 metformin Drugs 0.000 description 2
- PKWDZWYVIHVNKS-UHFFFAOYSA-N netoglitazone Chemical compound FC1=CC=CC=C1COC1=CC=C(C=C(CC2C(NC(=O)S2)=O)C=C2)C2=C1 PKWDZWYVIHVNKS-UHFFFAOYSA-N 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 229960004738 nicotinyl alcohol Drugs 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 2
- 229960001243 orlistat Drugs 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 2
- 229960003243 phenformin Drugs 0.000 description 2
- 229960005095 pioglitazone Drugs 0.000 description 2
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 2
- 201000009104 prediabetes syndrome Diseases 0.000 description 2
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 2
- 229960003912 probucol Drugs 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 229960004586 rosiglitazone Drugs 0.000 description 2
- 239000003352 sequestering agent Substances 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 229950005143 sitosterol Drugs 0.000 description 2
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- 229960005371 tolbutamide Drugs 0.000 description 2
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 2
- 229960001641 troglitazone Drugs 0.000 description 2
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 102000000536 PPAR gamma Human genes 0.000 description 1
- 206010036049 Polycystic ovaries Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- -1 carboxylate anion Chemical class 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18359300P | 2000-02-18 | 2000-02-18 | |
| US60/183,593 | 2000-02-18 | ||
| PCT/US2001/004636 WO2001060807A1 (en) | 2000-02-18 | 2001-02-14 | Aryloxyacetic acids for diabetes and lipid disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003523336A JP2003523336A (ja) | 2003-08-05 |
| JP2003523336A5 true JP2003523336A5 (sr) | 2008-04-03 |
Family
ID=22673475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001560192A Withdrawn JP2003523336A (ja) | 2000-02-18 | 2001-02-14 | 糖尿病及び脂質障害のためのアリールオキシ酢酸 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1259494A4 (sr) |
| JP (1) | JP2003523336A (sr) |
| AU (1) | AU784722B2 (sr) |
| CA (1) | CA2400021A1 (sr) |
| CO (1) | CO5261629A1 (sr) |
| PE (1) | PE20011056A1 (sr) |
| WO (1) | WO2001060807A1 (sr) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7041691B1 (en) | 1999-06-30 | 2006-05-09 | Amgen Inc. | Compounds for the modulation of PPARγ activity |
| SE0000772D0 (sv) | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | Chemical compounds |
| EG26979A (en) | 2000-12-21 | 2015-03-01 | Astrazeneca Ab | Chemical compounds |
| JP2004521124A (ja) | 2001-02-09 | 2004-07-15 | メルク エンド カムパニー インコーポレーテッド | 糖尿病および脂質障害用の２−アリールオキシ−２−アリールアルカン酸類 |
| GB0121337D0 (en) | 2001-09-04 | 2001-10-24 | Astrazeneca Ab | Chemical compounds |
| GB0121621D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| GB0121622D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| PL216023B1 (pl) | 2001-09-08 | 2014-02-28 | Astrazeneca Ab | Pochodna benzotiadiazepiny, kompozycja farmaceutyczna zawierajaca pochodna benzotiadiazepiny oraz zastosowania pochodnej benzotiadiazepiny |
| EP1435946B8 (en) | 2001-09-14 | 2013-12-18 | Amgen Inc. | Linked biaryl compounds |
| US20050014807A1 (en) * | 2001-11-21 | 2005-01-20 | Adams Alan D | Therapeutic compounds for treating dyslipidemic conditions |
| JP2005517008A (ja) | 2002-02-05 | 2005-06-09 | イーライ・リリー・アンド・カンパニー | Ｐｐａｒモジュレーターとして用いるためのウレアリンカー誘導体 |
| AU2003208238A1 (en) * | 2002-03-11 | 2003-09-22 | TAYLOR, , Carla | Use of ppar alpha agonists for the treatment of vascular and renal diseases |
| WO2003088962A1 (en) * | 2002-04-16 | 2003-10-30 | Merck & Co., Inc. | Combination therapy using a ppar alpha/gamma agonist |
| GB0209467D0 (en) | 2002-04-25 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
| GB0213669D0 (en) | 2002-06-14 | 2002-07-24 | Astrazeneca Ab | Chemical compounds |
| AU2003251587A1 (en) * | 2002-08-22 | 2004-03-11 | Cornell Research Foundation, Inc. | Multifunctional cox-2 inhibitors |
| PL376325A1 (en) * | 2002-10-21 | 2005-12-27 | Janssen Pharmaceutica, N.V. | Substituted tetralins and indanes |
| NZ539432A (en) * | 2002-10-21 | 2008-04-30 | Janssen Pharmaceutica Nv | Treating syndrome X with substituted tetralins and indanes |
| NZ539451A (en) * | 2002-10-21 | 2008-03-28 | Janssen Pharmaceutica Nv | Substituted tetralin and indane derivatives and their use in therapy |
| JP2006512334A (ja) * | 2002-12-10 | 2006-04-13 | ノバルティス アクチエンゲゼルシャフト | Ｄｐｐ−ｉｖ阻害剤とｐｐａｒ−アルファ化合物の組み合わせ |
| PL377847A1 (pl) | 2003-01-14 | 2006-02-20 | Arena Pharmaceuticals Inc. | 1,2,3-Tripodstawione pochodne arylowe i heteroarylowe jako modulatory metabolizmu oraz profilaktyka i leczenie związanych z nim zaburzeń takich jak cukrzyca i hiperglikemia |
| ATE427106T1 (de) | 2003-01-20 | 2009-04-15 | Tno | Die verwendung von sphingolipiden zur senkung der cholesterin- und triglyzeridspiegel im plasma. |
| NL1022443C2 (nl) | 2003-01-20 | 2004-07-22 | Tno | Sphingolipiden voor verbetering van de samenstelling van de darmflora. |
| GB0304194D0 (en) | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
| EP1457206A1 (en) * | 2003-03-13 | 2004-09-15 | Fournier Laboratories Ireland Limited | Combined use of a fibrate and orlistat for the treatment of obesity |
| GB0307918D0 (en) | 2003-04-05 | 2003-05-14 | Astrazeneca Ab | Therapeutic use |
| SE0301010D0 (sv) * | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
| SE0301009D0 (sv) * | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
| EA010023B1 (ru) | 2003-07-14 | 2008-06-30 | Арена Фармасьютикалз, Инк. | Конденсированные арильные и гетероарильные производные в качестве модуляторов метаболизма и для профилактики и лечения расстройств, связанных с нарушением метаболизма |
| SA04250253B1 (ar) | 2003-08-21 | 2009-11-10 | استرازينيكا ايه بي | احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن |
| JP5154218B2 (ja) * | 2004-03-16 | 2013-02-27 | ネーデルランドセ オルガニサティエ フォール トエゲパスト−ナトールヴェテンシャッペリク オンデルゾエク ティエヌオー | ２型糖尿病、インスリン抵抗性及びメタボリック症候群の治療及び予防においてスフィンゴ脂質を使用する方法 |
| EP1576894A1 (en) * | 2004-03-16 | 2005-09-21 | Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO | The use of sphingolipids in the treatment and prevention of type 2 diabetes mellitus, insulin resistance and Metabolic Syndrome |
| WO2005105736A1 (en) | 2004-05-05 | 2005-11-10 | Novo Nordisk A/S | Novel compounds, their preparation and use |
| JP2007536343A (ja) | 2004-05-05 | 2007-12-13 | ノボ ノルディスク アクティーゼルスカブ | Ｐｐａｒアゴニストとしてのフェノキシ酢酸誘導体 |
| GB0415320D0 (en) | 2004-07-08 | 2004-08-11 | Astrazeneca Ab | Novel compounds |
| GB0418830D0 (en) | 2004-08-24 | 2004-09-22 | Astrazeneca Ab | Novel compounds |
| DE602005024836D1 (de) * | 2004-09-16 | 2010-12-30 | Merck Sharp & Dohme | Verbindungen zur behandlung von dyslipidämie und anderer lipidstörungen |
| US7601847B2 (en) | 2004-10-26 | 2009-10-13 | Wyeth | Preparation and purification of 4-(indazol-3-yl)phenols |
| EP1817282B1 (en) | 2004-11-23 | 2011-07-20 | AstraZeneca AB | Phenoxyacetic acid derivatives useful for treating respiratory diseases |
| ATE539741T1 (de) | 2004-11-30 | 2012-01-15 | Tno | Sphingolipide bei der behandlung und prävention von hepatischer steatose |
| WO2006059744A1 (ja) * | 2004-11-30 | 2006-06-08 | Nippon Chemiphar Co., Ltd. | ペルオキシソーム増殖剤活性化受容体δの活性化剤 |
| EP1861382B1 (en) * | 2005-03-04 | 2012-10-10 | Merck Sharp & Dohme Corp. | Fused aromatic compounds having anti-diabetic activity |
| EP1888050B1 (en) | 2005-05-17 | 2012-03-21 | Merck Sharp & Dohme Ltd. | cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid for the treatment of cancer |
| ES2372617T3 (es) | 2005-06-30 | 2012-01-24 | High Point Pharmaceuticals, Llc | Ácidos fenoxiacéticos como activadores de ppar-delta. |
| FR2890071B1 (fr) | 2005-08-30 | 2007-11-09 | Fournier Sa Sa Lab | Nouveaux composes de l'indole |
| FR2890072A1 (fr) | 2005-09-01 | 2007-03-02 | Fournier S A Sa Lab | Nouveaux composesde pyrrolopyridine |
| EP1937632A1 (en) | 2005-10-06 | 2008-07-02 | Astra Zeneca AB | Novel compounds |
| TW200745003A (en) | 2005-10-06 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
| CA2631390C (en) | 2005-12-22 | 2014-03-11 | Per Sauerberg | Phenoxy acetic acids as ppar delta activators |
| EP1999098A2 (en) | 2006-03-09 | 2008-12-10 | High Point Pharmaceuticals, LLC | Compounds that modulate ppar activity, their preparation and use |
| EP2155187B1 (en) | 2007-05-07 | 2016-05-25 | Merck Sharp & Dohme Corp. | Method of treatment using fused aromatic compounds having anti-diabetic activity |
| UA100983C2 (ru) | 2007-07-05 | 2013-02-25 | Астразенека Аб | Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты |
| US7919509B2 (en) | 2008-02-29 | 2011-04-05 | Kowa Company, Ltd. | 2-oxochromene derivatives |
| JP2013006769A (ja) * | 2009-10-08 | 2013-01-10 | Nippon Chemiphar Co Ltd | ペルオキシソーム増殖剤活性化受容体の活性化剤 |
| BR112013008100A2 (pt) | 2010-09-22 | 2016-08-09 | Arena Pharm Inc | "moduladores do receptor de gpr19 e o tratamento de distúrbios relacionados a eles." |
| RU2591188C2 (ru) | 2010-11-08 | 2016-07-10 | Альбирео Аб | Ингибиторы ibat для лечения заболеваний печени |
| JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
| EP3043789B1 (en) | 2013-09-09 | 2020-07-08 | vTv Therapeutics LLC | Use of a ppar-delta agonists for treating muscle atrophy |
| CA2952406A1 (en) | 2014-06-25 | 2015-12-30 | Ea Pharma Co., Ltd. | Solid formulation and method for preventing or reducing coloration thereof |
| EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
| AU2016205361C1 (en) | 2015-01-06 | 2021-04-08 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
| SI3310760T1 (sl) | 2015-06-22 | 2023-02-28 | Arena Pharmaceuticals, Inc. | Kristalinična L-argininska sol (R)-2-(7-(4-ciklopentil-3-(trifluorometil)benziloksi)-1,2,3,4- tetrahidrociklo-penta(b)indol-3-il)ocetne kisline za uporabo pri motnjah, povezanih z receptorjem S1P1 |
| US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
| US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| KR20190116416A (ko) | 2017-02-16 | 2019-10-14 | 아레나 파마슈티칼스, 인크. | 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법 |
| WO2019032026A1 (en) | 2017-08-09 | 2019-02-14 | Albireo Ab | CHOLESTYRAMINE GRANULES, ORAL FORMULATIONS OF CHOLESTYRAMINE AND THEIR USE |
| US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| EP3802504B1 (en) | 2018-06-05 | 2023-01-18 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
| US11802115B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
| US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
| IL293379A (en) | 2019-12-04 | 2022-07-01 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| JP2023504647A (ja) | 2019-12-04 | 2023-02-06 | アルビレオ・アクチボラグ | ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
| CA3158181A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| JP2023504644A (ja) | 2019-12-04 | 2023-02-06 | アルビレオ・アクチボラグ | ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
| CN111793066B (zh) * | 2020-07-17 | 2022-04-08 | 瀚海新拓(杭州)生物医药有限公司 | 苯并五元杂环磺酰胺类化合物、其制备方法、药物组合物及应用 |
| CA3186857A1 (en) | 2020-08-03 | 2022-02-10 | Per-Goran Gillberg | Benzothia(di)azepine compounds and their use as bile acid modulators |
| KR20230106651A (ko) | 2020-11-12 | 2023-07-13 | 알비레오 에이비 | 진행성 가족성 간내 담즙정체증(pfic)을 치료하기 위한 오데빅시바트 |
| CN116583504A (zh) | 2020-12-04 | 2023-08-11 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| WO2023147309A1 (en) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4728662A (en) * | 1977-11-21 | 1988-03-01 | Hoechst-Roussel Pharmaceuticals Inc. | 1,2-benzisoxazoloxyacetic acids and related compounds |
| US5776963A (en) * | 1989-05-19 | 1998-07-07 | Hoechst Marion Roussel, Inc. | 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility |
-
2001
- 2001-02-14 JP JP2001560192A patent/JP2003523336A/ja not_active Withdrawn
- 2001-02-14 CA CA002400021A patent/CA2400021A1/en not_active Abandoned
- 2001-02-14 WO PCT/US2001/004636 patent/WO2001060807A1/en active Application Filing
- 2001-02-14 AU AU38214/01A patent/AU784722B2/en not_active Ceased
- 2001-02-14 EP EP01910624A patent/EP1259494A4/en not_active Withdrawn
- 2001-02-15 CO CO01011989A patent/CO5261629A1/es not_active Application Discontinuation
- 2001-02-16 PE PE2001000178A patent/PE20011056A1/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003523336A5 (sr) | ||
| JP2006500384A5 (sr) | ||
| JP2004513076A5 (sr) | ||
| JP5275975B2 (ja) | 高脂血症の予防及び／又は治療剤 | |
| JP2010529203A5 (sr) | ||
| US11691959B2 (en) | Anti-inflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds | |
| JP2005502600A5 (sr) | ||
| RU2006107653A (ru) | Связующее вспомогательное вещество и приготовленная на его основе таблетка в форме капли | |
| JP2003523336A (ja) | 糖尿病及び脂質障害のためのアリールオキシ酢酸 | |
| JP2004536115A5 (sr) | ||
| JP6238460B2 (ja) | 脂質異常症治療剤 | |
| JP2009522292A5 (sr) | ||
| JP2009531280A5 (sr) | ||
| JP2005533810A (ja) | 新規な抗コレステロール組成物及びその使用方法 | |
| AU2003256911B2 (en) | PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders | |
| JP2007527433A5 (sr) | ||
| JP2017505285A (ja) | ホモ接合性家族性高コレステロール血症の治療 | |
| JP2007531764A5 (sr) | ||
| CA2646244A1 (en) | Tetracycline compounds and methods of treatment | |
| CN1300210A (zh) | 作为抗菌剂的异羟肟酸衍生物 | |
| CA2526989A1 (en) | Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors | |
| JP2019516709A5 (sr) | ||
| US6924295B2 (en) | Tetrahydroquinoline derivative compound and drug containing the compound as active ingredient | |
| WO2001036402A1 (fr) | Nouveaux derives de 2-(n-cyano-imino)thiazolidin-4-one | |
| US20150051144A1 (en) | Compounds for the treatment of dyslipidemia and other diseases |